BrainStorm Cell Therapeutics Presents at the 11th International Conference on Alzheimer's and Parkinson's Disease

BrainStorm Cell Therapeutics Presents at the 11th International Conference on 
Alzheimer's and Parkinson's Disease 
NEW YORK, NY and PETACH TIKVAH, ISRAEL -- (Marketwire) -- 03/08/13 --
 BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of
adult stem cell technologies for neurodegenerative diseases,
announced today a poster presentation of clinical and scientific data
at the 11th International Conference on Alzheimer's and Parkinson's
Diseases (AD/PD 2013) this week in Florence, Italy
(http://www2.kenes.com/adpd/Pages/Home.aspx). 
"We are excited to be presenting our NurOwn(TM) technology at this
important meeting," said Alon Natanson, Chief Executive Officer of
BrainStorm Cell Therapeutics. "The AD/PD Conference brings
international medical professionals together for a dynamic scientific
program revealing cutting-edge research and discoveries diagnosing,
preventing, and treating neurodegenerative diseases. We believe that
our groundbreaking data on NurOwn(TM) will be well received by the
attendees." 
In the coming months BrainStorm will be making a number of
presentations at various international medical and research
conferences as the scientific communities in Europe and the US are
closely following the company's progress with its clinical
development program.  
About NurOwn(TM)
 NurOwn is an autologous, adult stem cell therapy
technology that differentiates bone marrow-derived mesenchymal stem
cells (MSC) into specialized, neuron-supporting cells. These
neuron-supporting cells (known as "MSC-NTF" cells) secrete
neurotrophic, or nerve-growth, factors for PROTECTION of existing
motor neurons, PROMOTION of motor neuron growth, and RE-ESTABLISHMENT
of nerve-muscle interaction. The ability to differentiate mesenchymal
stem cells into MSC-NTF cells, and confirmation of their activity and
potency before transplantation, makes NurOwn a first-of-its-kind
approach for treating neurodegenerative diseases. More information
about NurOwn(TM) can be found at
http://brainstorm-cell.com/index.php/science-a-technology/-nurown. 
About BrainStorm Cell Therapeutics, Inc.
 BrainStorm Cell
Therapeutics, Inc. is a biotechnology company engaged in the
development of first-of-its-kind adult stem cell therapies derived
from autologous bone marrow cells 
for the treatment of
neurodegenerative diseases. The Company holds the rights to develop
and commercialize its NurOwn technology through an exclusive,
worldwide licensing agreement with Ramot, the technology transfer
company of Tel Aviv University. For more information, visit the
company's website at www.brainstorm-cell.com. 
Safe Harbor Statement - Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended to
identify these forward-looking statements. The potential risks and
uncertainties include, without limitation, risks associated with
BrainStorm's limited operating history, history of losses; minimal
working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key
executives and on its scientific consultants; ability to obtain
required regulatory approvals; and other factors detailed in
BrainStorm's annual report on Form 10-K and quarterly reports on Form
10-Q available at http://www.sec.gov. These factors should be
considered carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the beliefs,
expectations and opinions of management as of the date of this press
release. We do not assume any obligation to update forward-looking
statements to reflect actual results or assumptions if circumstances
or management's beliefs, expectations or opinions should change,
unless otherwise required by law. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. 
CONTACTS
BrainStorm Cell Therapeutics Inc. 
Mr. Alon Natanson
CEO 
Phone: +972-3-9236384 
info@brainstorm-cell.com 
www.brainstorm-cell.com  
LifeSci Advisors, LLC
Michael Rice
Founding Partner
646-597-6979
mrice@lifesciadvisors.com
www.LifeSciAdvisors.com 
 
 
Press spacebar to pause and continue. Press esc to stop.